Advertisement
Research Article

Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads

  • Richard O. Oduor,

    Affiliation: Opportunities for Partnering in Medicine, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    Current address: Department of Biochemistry and Biotechnology, Kenyatta University, Nairobi, Kenya

    X
  • Kayode K. Ojo,

    Affiliation: Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, United States of America

    X
  • Gareth P. Williams,

    Affiliation: High Throughput Screening Center of Emphasis, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    X
  • Francois Bertelli,

    Affiliation: High Throughput Screening Center of Emphasis, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    X
  • James Mills,

    Affiliation: Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    X
  • Louis Maes,

    Affiliation: Laboratory for Microbiology, Parasitology and Hygiene, University of Antwerp, Antwerp, Belgium

    X
  • David C. Pryde,

    Affiliation: Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    X
  • Tanya Parkinson mail,

    tanya.parkinson@pfizer.com

    Affiliation: Opportunities for Partnering in Medicine, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    X
  • Wesley C. Van Voorhis,

    Affiliation: Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, United States of America

    X
  • Tod P. Holler

    Affiliation: Opportunities for Partnering in Medicine, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom

    Current address: Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America

    X
  • Published: April 05, 2011
  • DOI: 10.1371/journal.pntd.0001017

About the Authors

Richard O. Oduor, Tanya Parkinson, Tod P. Holler
Opportunities for Partnering in Medicine, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom
Kayode K. Ojo, Wesley C. Van Voorhis
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, United States of America
Gareth P. Williams, Francois Bertelli
High Throughput Screening Center of Emphasis, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom
James Mills, David C. Pryde
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom
Louis Maes
Laboratory for Microbiology, Parasitology and Hygiene, University of Antwerp, Antwerp, Belgium

Corresponding Author

Email: tanya.parkinson@pfizer.com

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: ROO KKO GPW FB JM LM DCP TP WCVV TPH. Performed the experiments: ROO KKO GPW FB JM. Analyzed the data: ROO KKO GPW FB JM LM DCP TP WCVV TPH. Contributed reagents/materials/analysis tools: JM KKO. Wrote the paper: ROO TP TPH.